glimepiride has been researched along with Insulin Resistance in 55 studies
glimepiride: structure given in first source
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study provides evidence that, compared to glimepiride, saxagliptin more effectively achieves a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in T2D patients who are inadequately controlled with metformin monotherapy, especially in overweight patients with moderate hyperglycaemia and a relatively short duration of diabetes." | 9.30 | Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centr ( Bi, Y; Cheng, J; Gu, T; Li, D; Ma, J; Shao, J; Shi, B; Sun, Z; Xu, L; Zhang, H; Zhang, Q; Zhong, S; Zhu, D; Zhu, L, 2019) |
| "Several studies have demonstrated the decreased insulin resistance (IR) in persons with type 2 diabetes mellitus (T2DM) treated with glimepiride." | 9.30 | The differential influence of glimepiride and glibenclamide on insulin resistance and adiponectin levels in patients with type 2 diabetes. ( Bahtiri, E; Begolli, L; Blaslov, K; Car, N; Emini-Sadiku, M; Haliti, E, 2019) |
| "The aim of this study was to analyze the efficacy, insulin sensitivity and safety in the event of administering sulfonylurea-based drugs and metformin in combination with basal insulin." | 9.30 | A comparison study on efficacy, insulin sensitivity and safety of Glimepiride/Metformin fixed dose combination versus glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy. ( Chun, SW; Hong, JH; Kim, SJ; Lee, JM; Lim, DM; Park, KS; Park, KY; Yu, HM, 2019) |
| "To evaluate the effects of vildagliptin compared to glimepiride on glycemic control, insulin resistance and post-prandial lipemia." | 9.19 | Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. ( Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D, 2014) |
| "The aim of this study was to evaluate the effect of exenatide compared to glimepiride on body weight, glycemic control and insulin resistance in type 2 diabetic patients taking metformin." | 9.15 | Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. ( Bonaventura, A; Bossi, AC; Derosa, G; Fogari, E; Franzetti, IG; Guazzini, B; Maffioli, P; Putignano, P; Querci, F; Testori, G, 2011) |
| "Glimepiride appears to improve insulin resistance and atherosclerotic disorders." | 9.12 | Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. ( Ito, S; Koshiba, K; Nakaya, Y; Nomura, M, 2006) |
| "The primary aim of the present study was to compare the effect of long-term (12-month) combination treatment with glimepiride or rosiglitazone plus metformin on blood pressure in patients with type 2 diabetes mellitus (DM-2) and the metabolic syndrome." | 9.11 | Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. ( Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Fogari, E; Fogari, R; Gaddi, AV; Ghelfi, M; Piccinni, MN; Pricolo, F; Salvadeo, S, 2005) |
| "The goals of this study were to compare changes in measures of glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes who received pioglitazone or glimepiride for 1 year." | 9.11 | Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial. ( Antúnez, O; Fabián, G; Flores-Lozano, F; Garza, E; González Gálvez, G; Herz, M; Johns, D; Konkoy, C; Morales, H; Tan, M; Zúñiga Guajardo, S, 2004) |
| "We investigated the effect of glimepiride, a third-generation sulfonylurea hypoglycemic agent, on insulin resistance in elderly patients with type 2 diabetes, in connection with plasma adiponectin and 8-epi-prostagrandin F2alpha (8-epi-PGF2alpha), an oxidative stress marker." | 9.10 | Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. ( Fukatsu, A; Hayashi, T; Iguchi, A; Kano, H; Matsui-Hirai, H; Miyazaki, A; Nomura, N; Suzuki, Y; Tsunekawa, T, 2003) |
| "Treatment with glimepiride did not improve insulin sensitivity in a patient with type A insulin resistance syndrome carrying Ile1143Phe heterozygous mutation in the INSR gene." | 7.88 | Glimepiride treatment in a patient with type A insulin resistance syndrome due to a novel heterozygous missense mutation in the insulin receptor gene. ( He, X; Huang, Z; Li, Y; Liao, Z; Liu, J; Ng, K; Wan, X; Xu, L, 2018) |
| "Dyslipidemia in patients with type 2 diabetes is characterized by elevated triglyceride levels, decreased high-density lipoprotein (HDL) cholesterol, and a predominance of small dense low-density lipoprotein (LDL) particles." | 6.76 | PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. ( Forst, T; Fuchs, W; Lehmann, U; Lobmann, R; Merke, J; Müller, J; Pfützner, A; Schöndorf, T; Tschöpe, D, 2011) |
| "Insulin resistance was defined by elevated intact proinsulin values or homeostasis model assessment for insulin resistance score of more than 2." | 6.72 | Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. ( Forst, T; Hamann, A; Matthaei, S; Pfützner, A; Schöndorf, T; Seidel, D; Winkler, K, 2006) |
| "It is important to choose the optimal treatment for DM in myotonic dystrophy, because the patients have hyperinsulinemia caused by specific mechanism and could not reduce the insulin resistance." | 5.33 | Low-dose metformin improves hyperglycaemia related to myotonic dystrophy. ( Komiya, I; Kouki, T; Nakachi, A; Takasu, N; Tamanaha, T; Tawata, M, 2005) |
| "Several studies have demonstrated the decreased insulin resistance (IR) in persons with type 2 diabetes mellitus (T2DM) treated with glimepiride." | 5.30 | The differential influence of glimepiride and glibenclamide on insulin resistance and adiponectin levels in patients with type 2 diabetes. ( Bahtiri, E; Begolli, L; Blaslov, K; Car, N; Emini-Sadiku, M; Haliti, E, 2019) |
| "This study provides evidence that, compared to glimepiride, saxagliptin more effectively achieves a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in T2D patients who are inadequately controlled with metformin monotherapy, especially in overweight patients with moderate hyperglycaemia and a relatively short duration of diabetes." | 5.30 | Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centr ( Bi, Y; Cheng, J; Gu, T; Li, D; Ma, J; Shao, J; Shi, B; Sun, Z; Xu, L; Zhang, H; Zhang, Q; Zhong, S; Zhu, D; Zhu, L, 2019) |
| "The aim of this study was to analyze the efficacy, insulin sensitivity and safety in the event of administering sulfonylurea-based drugs and metformin in combination with basal insulin." | 5.30 | A comparison study on efficacy, insulin sensitivity and safety of Glimepiride/Metformin fixed dose combination versus glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy. ( Chun, SW; Hong, JH; Kim, SJ; Lee, JM; Lim, DM; Park, KS; Park, KY; Yu, HM, 2019) |
| "Pioglitazone suppresses RAGE expression and increases circulating sRAGE/esRAGE, and those activities are not necessarily dependent on plasma glucose or insulin resistance levels." | 5.19 | Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: randomized controlled trial (PioRAGE). ( Emoto, M; Fujii, H; Fukui, M; Fukumoto, S; Inaba, M; Koyama, H; Monden, M; Mori, K; Morioka, T; Nishizawa, Y; Shoji, T; Tanaka, S, 2014) |
| " We evaluated the following variables: BMI; glycaemic control; fasting plasma insulin; homeostatic model assessment of insulin resistance index; fasting plasma proinsulin; glucagon; lipid profile; adiponectin; high-sensitivity C-reactive protein; interleukin-6; and tumour necrosis factor-α." | 5.19 | Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes. ( Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D, 2014) |
| "To evaluate the effects of vildagliptin compared to glimepiride on glycemic control, insulin resistance and post-prandial lipemia." | 5.19 | Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. ( Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D, 2014) |
| " Here, we examined whether pioglitazone plus nateglinide (PIO) interferes with hepatocellular lipid (HCL) content and/or improves insulin sensitivity in well-controlled non-obese patients with type 2 diabetes mellitus (T2DM)." | 5.17 | Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes. ( Anderwald, CH; Bernroider, E; Brehm, A; Krebs, M; Krssak, M; Nowotny, P; Phielix, E; Roden, M; Schmid, AI, 2013) |
| "The aim of this study was to evaluate the effect of exenatide compared to glimepiride on body weight, glycemic control and insulin resistance in type 2 diabetic patients taking metformin." | 5.15 | Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. ( Bonaventura, A; Bossi, AC; Derosa, G; Fogari, E; Franzetti, IG; Guazzini, B; Maffioli, P; Putignano, P; Querci, F; Testori, G, 2011) |
| "In T2DM patients, pioglitazone was associated with improvement in some measures of left ventricular diastolic function, myocardial glucose uptake, and whole-body insulin sensitivity." | 5.14 | Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. ( Bax, JJ; de Jong, HW; de Roos, A; Diamant, M; Heine, RJ; Kamp, O; Lamb, HJ; Lammertsma, AA; Lubberink, M; Paulus, WJ; Rijzewijk, LJ; Romijn, JA; Smit, JW; van der Meer, RW, 2009) |
| "The aim of the study was to compare the effects of vildagliptin added to pioglitazone or glimepiride on metabolic and insulin resistance related-indices in poorly controlled type 2 diabetic patients (T2DM)." | 5.14 | Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. ( Ciccarelli, L; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Mereu, R; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA, 2010) |
| "Glimepiride appears to improve insulin resistance and atherosclerotic disorders." | 5.12 | Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. ( Ito, S; Koshiba, K; Nakaya, Y; Nomura, M, 2006) |
| "The goals of this study were to compare changes in measures of glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes who received pioglitazone or glimepiride for 1 year." | 5.11 | Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial. ( Antúnez, O; Fabián, G; Flores-Lozano, F; Garza, E; González Gálvez, G; Herz, M; Johns, D; Konkoy, C; Morales, H; Tan, M; Zúñiga Guajardo, S, 2004) |
| " Metformin and pioglitazone had beneficial effects on lipid levels, improved insulin sensitivity and improved insulin secretion also." | 5.11 | Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians. ( Ramachandran, A; Salini, J; Snehalatha, C; Vijay, V, 2004) |
| "The primary aim of the present study was to compare the effect of long-term (12-month) combination treatment with glimepiride or rosiglitazone plus metformin on blood pressure in patients with type 2 diabetes mellitus (DM-2) and the metabolic syndrome." | 5.11 | Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. ( Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Fogari, E; Fogari, R; Gaddi, AV; Ghelfi, M; Piccinni, MN; Pricolo, F; Salvadeo, S, 2005) |
| "The current study demonstrates that glimepiride improves both first and second phases of insulin secretion, but not insulin sensitivity, in individuals with type 2 diabetes." | 5.10 | Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. ( Gerich, J; Gooding, WE; Korytkowski, M; Reid, L; Tedesco, MB; Thomas, A, 2002) |
| "We investigated the effect of glimepiride, a third-generation sulfonylurea hypoglycemic agent, on insulin resistance in elderly patients with type 2 diabetes, in connection with plasma adiponectin and 8-epi-prostagrandin F2alpha (8-epi-PGF2alpha), an oxidative stress marker." | 5.10 | Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. ( Fukatsu, A; Hayashi, T; Iguchi, A; Kano, H; Matsui-Hirai, H; Miyazaki, A; Nomura, N; Suzuki, Y; Tsunekawa, T, 2003) |
| "Treatment with glimepiride did not improve insulin sensitivity in a patient with type A insulin resistance syndrome carrying Ile1143Phe heterozygous mutation in the INSR gene." | 3.88 | Glimepiride treatment in a patient with type A insulin resistance syndrome due to a novel heterozygous missense mutation in the insulin receptor gene. ( He, X; Huang, Z; Li, Y; Liao, Z; Liu, J; Ng, K; Wan, X; Xu, L, 2018) |
| "Glimepiride can rapidly and stably improve glycemic control and lipoprotein metabolism, significantly alleviate insulin resistance and enhance fibrinolytic activity." | 3.76 | Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus. ( Du, W; Huang, QX; Liu, L; Liu, YH; Xie, XM; Xu, DY; Zhao, SP, 2010) |
| "The increased GLUT4 protein expression and glucose utilization in oxidative muscle and the increased insulin sensitivity and glycogen storage in liver evidence the insulin-sensitizer effect of glimepiride, which must be important to enable the glimepiride drug to promote an efficient glycaemic control." | 3.74 | Glimepiride as insulin sensitizer: increased liver and muscle responses to insulin. ( Hirabara, SM; Hirata, AE; Machado, UF; Mori, RC; Okamoto, MM, 2008) |
| "To investigate the effect of glimepiride and metformin on free fatty acid (FFA) in patients with Type 2 diabetes mellitus and to further study the relationship between free fatty acid and insulin resistance in patients with Type 2 diabetes mellitus." | 3.72 | [Effects of glimepiride and metformin on free fatty acid in patients with Type 2 diabetes mellitus]. ( Feng, Q; Mao, JP; Tang, JZ; Tang, WL; Yang, ZF; Zhou, ZG, 2004) |
| "Insulin resistance was improved significantly with HOMA-IR decreasing from 2." | 2.78 | Efficacy and safety of glimepiride as initial treatment in Chinese patients with Type 2 diabetes mellitus. ( Duan, WR; Gao, Y; Guo, XH; Han, P; Lv, XF; Yang, HZ; Zhang, XZ, 2013) |
| "In newly diagnosed type 2 diabetes, therapy with oral drugs + insulin has had favourable outcomes on recovery and maintenance of β-cell function and protracted glycaemic remission compared with treatment with oral drugs alone." | 2.77 | Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes. ( Chen, YM; Lu, HY; Mu, PW; Shu, J; Wang, MM; Wen, XQ; Xie, RY; Zeng, LY; Zhang, YH, 2012) |
| "Dyslipidemia in patients with type 2 diabetes is characterized by elevated triglyceride levels, decreased high-density lipoprotein (HDL) cholesterol, and a predominance of small dense low-density lipoprotein (LDL) particles." | 2.76 | PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. ( Forst, T; Fuchs, W; Lehmann, U; Lobmann, R; Merke, J; Müller, J; Pfützner, A; Schöndorf, T; Tschöpe, D, 2011) |
| "Two hundred seventy-one type 2 diabetes mellitus patients with poor glycemic control and who were overweight were enrolled in this study." | 2.74 | Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Salvadeo, SA, 2009) |
| "Twenty-eight patients with type 2 diabetes already on metformin, without known cardiovascular disease, were randomized in 2 groups; glimepiride (4 mg od) was added in group A (n=14) and pioglitazone (30 mg od) in group B (n=14) for 6 months." | 2.74 | Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes. ( Kanioglou, C; Katsouras, CS; Kazakos, N; Kolettis, T; Liveris, K; Makriyiannis, D; Michalis, LK; Naka, KK; Papathanassiou, K; Pappas, K; Tsatsoulis, A, 2009) |
| "One hundred twenty (120) patients with type 2 diabetes mellitus were randomized and treated with glimepiride plus rosiglitazone or glimepiride plus metformin for 12 weeks." | 2.73 | Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. ( Ahn, CW; Cha, BS; Chung, CH; Kang, ES; Kim, DJ; Kim, HJ; Kim, SH; Lee, HC; Lee, KW; Nam, CM; Nam, M, 2007) |
| "This study assessed the efficacy and safety of two different dosing regimens of fixed-dose combination (FDC) rosiglitazone (RSG) plus glimepiride (GLIM) compared with RSG or GLIM monotherapy in drug-naive subjects with type 2 diabetes mellitus (T2DM)." | 2.73 | Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes. ( Chou, HS; Ferreira-Cornwell, C; Goldstein, BJ; Jones, AR; Krebs, J; Palmer, JP; Waterhouse, B, 2008) |
| "Strategies for the addition of RSG in combination with GLIM were evaluated with data from two randomized, double-blind, placebo (PBO)-controlled studies." | 2.73 | Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes. ( Chou, HS; Hamann, A; Matthaei, S; Rosenstock, J; Seidel, DK, 2008) |
| "Insulin resistance was defined by elevated intact proinsulin values or homeostasis model assessment for insulin resistance score of more than 2." | 2.72 | Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. ( Forst, T; Hamann, A; Matthaei, S; Pfützner, A; Schöndorf, T; Seidel, D; Winkler, K, 2006) |
| " In the diabetic patients, glimepiride tablets were administered orally, initially at 2 mg once daily in the morning, with the dosage increased by 1 mg every 2 weeks until fasting plasma glucose (FPG) decreased to 6." | 2.71 | Effects of glimepiride on insulin secretion and sensitivity in patients with recently diagnosed type 2 diabetes mellitus. ( Kabadi, MU; Kabadi, UM, 2004) |
| "Current agents for the treatment of Type 2 diabetes mellitus improve the metabolic profile but do not reinstate normality." | 2.40 | New agents for Type 2 diabetes. ( Bailey, CJ; Nattrass, M, 1999) |
| "For T2DM combined with NAFLD patients, the saxagliptin treatment could not only effectively control blood glucose but also attenuate insulin resistance and inflammatory injury of the liver to improve fatty liver further." | 1.51 | The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data. ( Fan, B; Guo, XL; Li, JJ; Zhang, P; Zheng, ZS, 2019) |
| "It is important to choose the optimal treatment for DM in myotonic dystrophy, because the patients have hyperinsulinemia caused by specific mechanism and could not reduce the insulin resistance." | 1.33 | Low-dose metformin improves hyperglycaemia related to myotonic dystrophy. ( Komiya, I; Kouki, T; Nakachi, A; Takasu, N; Tamanaha, T; Tawata, M, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (5.45) | 18.2507 |
| 2000's | 29 (52.73) | 29.6817 |
| 2010's | 21 (38.18) | 24.3611 |
| 2020's | 2 (3.64) | 2.80 |
| Authors | Studies |
|---|---|
| Werida, RH | 1 |
| Ramzy, A | 1 |
| Ebrahim, YN | 1 |
| Helmy, MW | 1 |
| Abdel-Latif, RG | 1 |
| Ahmed, AF | 1 |
| Heeba, GH | 1 |
| Chon, S | 1 |
| Rhee, SY | 1 |
| Ahn, KJ | 1 |
| Baik, SH | 1 |
| Park, Y | 1 |
| Nam, MS | 1 |
| Lee, KW | 2 |
| Yoo, SJ | 1 |
| Koh, G | 1 |
| Lee, DH | 1 |
| Kim, YS | 1 |
| Woo, JT | 1 |
| Huang, Z | 1 |
| Liu, J | 1 |
| Ng, K | 1 |
| Wan, X | 1 |
| Xu, L | 2 |
| He, X | 1 |
| Liao, Z | 1 |
| Li, Y | 1 |
| Niedowicz, DM | 1 |
| Özcan, S | 1 |
| Nelson, PT | 1 |
| Gu, T | 1 |
| Ma, J | 1 |
| Zhang, Q | 1 |
| Zhu, L | 1 |
| Zhang, H | 1 |
| Cheng, J | 1 |
| Shi, B | 1 |
| Li, D | 1 |
| Shao, J | 1 |
| Sun, Z | 1 |
| Zhong, S | 1 |
| Bi, Y | 1 |
| Zhu, D | 1 |
| Li, JJ | 1 |
| Zhang, P | 1 |
| Fan, B | 1 |
| Guo, XL | 1 |
| Zheng, ZS | 1 |
| Emini-Sadiku, M | 1 |
| Car, N | 1 |
| Begolli, L | 1 |
| Blaslov, K | 1 |
| Haliti, E | 1 |
| Bahtiri, E | 1 |
| Yu, HM | 1 |
| Kim, SJ | 1 |
| Chun, SW | 1 |
| Park, KY | 1 |
| Lim, DM | 1 |
| Lee, JM | 1 |
| Hong, JH | 1 |
| Park, KS | 1 |
| Phielix, E | 1 |
| Brehm, A | 1 |
| Bernroider, E | 1 |
| Krssak, M | 1 |
| Anderwald, CH | 1 |
| Krebs, M | 1 |
| Schmid, AI | 1 |
| Nowotny, P | 1 |
| Roden, M | 1 |
| Koyama, H | 1 |
| Tanaka, S | 1 |
| Monden, M | 1 |
| Shoji, T | 2 |
| Morioka, T | 1 |
| Fukumoto, S | 1 |
| Mori, K | 1 |
| Emoto, M | 1 |
| Fukui, M | 1 |
| Fujii, H | 1 |
| Nishizawa, Y | 1 |
| Inaba, M | 1 |
| Derosa, G | 6 |
| Bonaventura, A | 3 |
| Bianchi, L | 2 |
| Romano, D | 2 |
| Fogari, E | 4 |
| D'Angelo, A | 4 |
| Maffioli, P | 5 |
| El-Haggar, SM | 1 |
| Farrag, WF | 1 |
| Kotkata, FA | 1 |
| Seino, Y | 1 |
| Kuwata, H | 1 |
| Yabe, D | 1 |
| Papathanassiou, K | 1 |
| Naka, KK | 1 |
| Kazakos, N | 1 |
| Kanioglou, C | 1 |
| Makriyiannis, D | 1 |
| Pappas, K | 1 |
| Katsouras, CS | 1 |
| Liveris, K | 1 |
| Kolettis, T | 1 |
| Tsatsoulis, A | 1 |
| Michalis, LK | 1 |
| van der Meer, RW | 1 |
| Rijzewijk, LJ | 1 |
| de Jong, HW | 1 |
| Lamb, HJ | 1 |
| Lubberink, M | 1 |
| Romijn, JA | 1 |
| Bax, JJ | 1 |
| de Roos, A | 1 |
| Kamp, O | 1 |
| Paulus, WJ | 1 |
| Heine, RJ | 1 |
| Lammertsma, AA | 1 |
| Smit, JW | 1 |
| Diamant, M | 1 |
| Gropler, RJ | 1 |
| Salvadeo, SA | 2 |
| Ferrari, I | 3 |
| Gravina, A | 1 |
| Mereu, R | 2 |
| Palumbo, I | 1 |
| Cicero, AF | 2 |
| Sharma, AK | 1 |
| Srinivasan, BP | 1 |
| Xu, DY | 1 |
| Zhao, SP | 1 |
| Huang, QX | 1 |
| Du, W | 1 |
| Liu, YH | 1 |
| Liu, L | 1 |
| Xie, XM | 1 |
| Ragonesi, PD | 1 |
| Querci, F | 2 |
| Franzetti, IG | 2 |
| Gadaleta, G | 1 |
| Ciccarelli, L | 2 |
| Piccinni, MN | 2 |
| Pfützner, A | 4 |
| Derwahl, M | 1 |
| Jacob, S | 1 |
| Hohberg, C | 2 |
| Blümner, E | 1 |
| Lehmann, U | 2 |
| Fuchs, W | 2 |
| Forst, T | 4 |
| Schöndorf, T | 2 |
| Tschöpe, D | 1 |
| Lobmann, R | 1 |
| Merke, J | 1 |
| Müller, J | 1 |
| Putignano, P | 1 |
| Bossi, AC | 1 |
| Guazzini, B | 1 |
| Testori, G | 1 |
| Mu, PW | 1 |
| Chen, YM | 1 |
| Lu, HY | 1 |
| Wen, XQ | 1 |
| Zhang, YH | 1 |
| Xie, RY | 1 |
| Shu, J | 1 |
| Wang, MM | 1 |
| Zeng, LY | 1 |
| Goncharenko, ON | 1 |
| Ametov, AS | 1 |
| Isakova, MR | 1 |
| Guo, XH | 1 |
| Lv, XF | 1 |
| Han, P | 1 |
| Zhang, XZ | 1 |
| Yang, HZ | 1 |
| Duan, WR | 1 |
| Gao, Y | 1 |
| Korytkowski, M | 1 |
| Thomas, A | 1 |
| Reid, L | 1 |
| Tedesco, MB | 1 |
| Gooding, WE | 1 |
| Gerich, J | 1 |
| Nakamura, N | 1 |
| Tsunekawa, T | 1 |
| Hayashi, T | 1 |
| Suzuki, Y | 1 |
| Matsui-Hirai, H | 1 |
| Kano, H | 1 |
| Fukatsu, A | 1 |
| Nomura, N | 1 |
| Miyazaki, A | 1 |
| Iguchi, A | 1 |
| Tang, L | 1 |
| Yang, YS | 1 |
| Ji, RY | 1 |
| Kabadi, MU | 1 |
| Kabadi, UM | 1 |
| Tan, M | 1 |
| Johns, D | 1 |
| González Gálvez, G | 1 |
| Antúnez, O | 1 |
| Fabián, G | 1 |
| Flores-Lozano, F | 1 |
| Zúñiga Guajardo, S | 1 |
| Garza, E | 1 |
| Morales, H | 1 |
| Konkoy, C | 1 |
| Herz, M | 1 |
| Ramachandran, A | 1 |
| Snehalatha, C | 1 |
| Salini, J | 1 |
| Vijay, V | 1 |
| Shimizu, H | 1 |
| Monden, T | 1 |
| Nagai, T | 1 |
| Shoda, Y | 1 |
| Sato, T | 1 |
| Yamada, M | 1 |
| Mori, M | 1 |
| Inukai, K | 2 |
| Watanabe, M | 2 |
| Nakashima, Y | 2 |
| Takata, N | 2 |
| Isoyama, A | 1 |
| Sawa, T | 2 |
| Kurihara, S | 2 |
| Awata, T | 2 |
| Katayama, S | 2 |
| Kouki, T | 1 |
| Takasu, N | 1 |
| Nakachi, A | 1 |
| Tamanaha, T | 1 |
| Komiya, I | 1 |
| Tawata, M | 1 |
| Kawamori, R | 1 |
| Tanaka, M | 1 |
| Kashiwabara, H | 1 |
| Yokota, K | 1 |
| Suzuki, M | 1 |
| Tang, JZ | 1 |
| Mao, JP | 1 |
| Yang, ZF | 1 |
| Zhou, ZG | 1 |
| Tang, WL | 1 |
| Feng, Q | 1 |
| Lübben, G | 1 |
| Pahler, S | 1 |
| Pfützner, AH | 1 |
| Kann, P | 1 |
| Gaddi, AV | 1 |
| Salvadeo, S | 1 |
| Pricolo, F | 1 |
| Ghelfi, M | 1 |
| Fogari, R | 1 |
| Seidel, D | 1 |
| Winkler, K | 1 |
| Matthaei, S | 2 |
| Hamann, A | 2 |
| Koshiba, K | 1 |
| Nomura, M | 1 |
| Nakaya, Y | 1 |
| Ito, S | 1 |
| Kim, HJ | 1 |
| Kang, ES | 1 |
| Kim, DJ | 1 |
| Kim, SH | 1 |
| Ahn, CW | 1 |
| Cha, BS | 1 |
| Nam, M | 1 |
| Chung, CH | 1 |
| Nam, CM | 1 |
| Lee, HC | 1 |
| Chou, HS | 2 |
| Palmer, JP | 1 |
| Jones, AR | 1 |
| Waterhouse, B | 1 |
| Ferreira-Cornwell, C | 1 |
| Krebs, J | 1 |
| Goldstein, BJ | 1 |
| Fehér, J | 1 |
| Lengyel, G | 1 |
| Rosenstock, J | 1 |
| Seidel, DK | 1 |
| Mori, RC | 1 |
| Hirabara, SM | 1 |
| Hirata, AE | 1 |
| Okamoto, MM | 1 |
| Machado, UF | 1 |
| Müller, G | 1 |
| Wied, S | 1 |
| Satoh, Y | 1 |
| Nattrass, M | 1 |
| Bailey, CJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Saxagliptin and Glimepiride in Chinese Patients With Type 2 Diabetes Controlled Inadequately With Metformin Monotherapy (SPECIFY Study) : a 48-week, Multi-center, Randomized, Open-label Trial[NCT02280486] | Phase 4 | 388 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Effects of Glimepiride Monotherapy Versus Combined Neteglinide-Pioglitazone Therapy on Insulin Sensitivity in Type 2 Diabetic Patients[NCT01570660] | 24 participants (Actual) | Interventional | 2002-02-28 | Completed | |||
| Physicians Committee for Responsible Medicine, A Randomized, Crossover Trial of the Effect of a Dietary Intervention on Intracellular Lipid, Insulin Sensitivity, and Glycemic Control in Type 2 Diabetes[NCT04088981] | 60 participants (Anticipated) | Interventional | 2024-07-31 | Suspended (stopped due to The study was not initiated due to COVID-19 restrictions.) | |||
| Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus[NCT01761318] | Phase 4 | 50 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| The Effect of Adding Vildagliptin Versus Glimepiride to Metformin on Markers of Inflammation, Thrombosis, and Atherosclerosis in Diabetic Patients With Symptomatic Coronary Artery Diseases[NCT03693560] | Phase 4 | 80 participants (Actual) | Interventional | 2018-10-08 | Completed | ||
| Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetic Patients With Coronary Artery Disease[NCT01604213] | Phase 4 | 60 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| Effects of a Pioglitazone/Metformin Fixed Combination in Comparison to Metformin in Combination With Glimepiride on Diabetic Dyslipidemia[NCT00770653] | Phase 3 | 305 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes[NCT02526810] | Phase 4 | 70 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono- Therapy in Chinese Type 2 Diabetes Mellitus (T2DM)[NCT00908921] | Phase 4 | 391 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The change between Adiponectin collected at week 24 or final visit and Adiponectin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | μg/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 6.79 |
| Glimepiride 2 mg and Metformin 850 mg BID | 0.72 |
The change between Diastolic Blood Pressure measured at week 24 or final visit and Diastolic Blood Pressure measured at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -1.3 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.1 |
The change between the value of E-Selectin collected at week 24 or final visit and E-Selectin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -3.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.5 |
The change between the 0.30 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 1.3 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.4 |
The change between the 0.60 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 2.4 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.5 |
The change between the 1.20 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 3.2 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.1 |
The change between the 12.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 2.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.3 |
The change between the 3.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 3.3 |
| Glimepiride 2 mg and Metformin 850 mg BID | -.15 |
The change between the 30.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 2.5 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.3 |
The change between the 6.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 3.1 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.4 |
The change between the 60.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 2.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.3 |
The change between Fasting Glucose collected at week 24 or final visit and Fasting Glucose collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -21.6 |
| Glimepiride 2 mg and Metformin 850 mg BID | -21.1 |
The change between Fasting Intact Proinsulin collected at week 24 or final visit and Fasting Intact Proinsulin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | pmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -5.18 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.11 |
The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 or final visit and Glycosylated Hemoglobin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -0.83 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.95 |
The change between the value of High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at week 24 or final visit and High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/L (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -0.87 |
| Glimepiride 2 mg and Metformin 850 mg BID | 0.00 |
The change between the value of High Sensitivity C-reactive Protein collected at week 24 or final visit and High Sensitivity C-reactive Protein collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -0.21 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.04 |
The change between HDL-Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 3.3 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.4 |
The change between High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at week 24 or final visit and High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 0.1 |
| Glimepiride 2 mg and Metformin 850 mg BID | 0.3 |
The change between Low-Density Lipoprotein Cholesterol collected at week 24 or final visit and Low-Density Lipoprotein Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 9.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | 11.2 |
The change between the value of Low-Density Lipoprotein Subfractions collected at week 24 or final visit and Low-Density Lipoprotein Subfractions collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 6.2 |
| Glimepiride 2 mg and Metformin 850 mg BID | 6.1 |
The change between the value of Baseline in Matrix Metallo Proteinase-9 collected at week 24 or final visit and Baseline in Matrix Metallo Proteinase-9 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 31.4 |
| Glimepiride 2 mg and Metformin 850 mg BID | 51.6 |
The change between the value of Nitrotyrosine collected at week 24 or final visit and Nitrotyrosine collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -2.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | 32.5 |
The change between the value of Platelet Function by PFA 100 collected at week 24 or final visit and Platelet Function by PFA 100 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | sec (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -30.3 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.0 |
The change between the value of Soluble CD40 Ligand collected at week 24 or final visit and Soluble CD40 Ligand collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | pg/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -40.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | 102.4 |
The change between the value of Baseline in Soluble Intracellular Adhesion molecule at week 24 or final visit and Baseline in Soluble Intracellular Adhesion molecule collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -13.0 |
| Glimepiride 2 mg and Metformin 850 mg BID | -3.2 |
The change between the value of Soluble Vascular Cell Adhesion Molecule collected at week 24 or final visit and Soluble Vascular Cell Adhesion Molecule collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 11.6 |
| Glimepiride 2 mg and Metformin 850 mg BID | 3.3 |
The change between Systolic Blood Pressure measured at week 24 or final visit and Systolic Blood Pressure measured at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -2.5 |
| Glimepiride 2 mg and Metformin 850 mg BID | 0.5 |
The change between the value of Thromboxane B2 collected at week 24 or final visit and Thromboxane B2 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | pg/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -216.4 |
| Glimepiride 2 mg and Metformin 850 mg BID | 527.8 |
The change between the value of Triglycerides collected at week 24 or final visit and Triglycerides collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -40.9 |
| Glimepiride 2 mg and Metformin 850 mg BID | -16.7 |
The change between the value of Von-Willebrand Factor collected at week 24 or final visit and Von-Willebrand Factor collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -19.5 |
| Glimepiride 2 mg and Metformin 850 mg BID | 1.4 |
The change between the Intake of study medication greater than 80% at week 24 or final visit and Baseline and the Intake of study medication greater than 80% at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | participants (Number) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 136 |
| Glimepiride 2 mg and Metformin 850 mg BID | 137 |
The increase in High-Density Lipoprotein (HDL) Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 3.2 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.3 |
6 reviews available for glimepiride and Insulin Resistance
| Article | Year |
|---|---|
Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives.
Topics: Animals; Asian People; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like | 2016 |
[Glimepiride].
Topics: Adenosine Triphosphate; Animals; ATP-Binding Cassette Transporters; Clinical Trials as Topic; Diabet | 2002 |
[Progress in studies on antidiabetic agents].
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insuli | 2001 |
[Therapies for newly-onset diabetic patients].
Topics: Acarbose; Cyclohexanes; Diabetes Mellitus, Type 2; Diet Therapy; Enzyme Inhibitors; Exercise Therapy | 2005 |
[Pharmacology of glimepiride].
Topics: Adenosine Triphosphate; Animals; ATP-Binding Cassette Transporters; Blood Glucose; Cardiovascular Sy | 1997 |
New agents for Type 2 diabetes.
Topics: Anti-Obesity Agents; Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Design; Humans; Hypoglyce | 1999 |
32 trials available for glimepiride and Insulin Resistance
| Article | Year |
|---|---|
Effect of coadministration of omega-3 fatty acids with glimepiride on glycemic control, lipid profile, irisin, and sirtuin-1 in type 2 diabetes mellitus patients: a randomized controlled trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Omega-3; Fibronectins; G | 2023 |
Long-term effects on glycaemic control and β-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Foll | 2018 |
Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centr
Topics: Adamantane; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Female; | 2019 |
The differential influence of glimepiride and glibenclamide on insulin resistance and adiponectin levels in patients with type 2 diabetes.
Topics: Adiponectin; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agent | 2019 |
A comparison study on efficacy, insulin sensitivity and safety of Glimepiride/Metformin fixed dose combination versus glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Hu | 2019 |
Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
Topics: Adiponectin; Blood Glucose; Body Mass Index; C-Reactive Protein; Cyclohexanes; Diabetes Mellitus, Ty | 2013 |
Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
Topics: Adiponectin; Blood Glucose; Body Mass Index; C-Reactive Protein; Cyclohexanes; Diabetes Mellitus, Ty | 2013 |
Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
Topics: Adiponectin; Blood Glucose; Body Mass Index; C-Reactive Protein; Cyclohexanes; Diabetes Mellitus, Ty | 2013 |
Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
Topics: Adiponectin; Blood Glucose; Body Mass Index; C-Reactive Protein; Cyclohexanes; Diabetes Mellitus, Ty | 2013 |
Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: randomized controlled trial (PioRAGE).
Topics: Adult; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hy | 2014 |
Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes.
Topics: Adamantane; Adiponectin; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Cholesterol, HDL; Chol | 2014 |
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method | 2014 |
Effect of ketotifen in obese patients with type 2 diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Female; Huma | 2015 |
Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Humans; Hypoglycemic | 2009 |
Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.
Topics: Adenosine Triphosphate; Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combi | 2009 |
Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Body Mass Index; Caloric Restriction; Diabetes Mel | 2009 |
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fema | 2010 |
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fema | 2010 |
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fema | 2010 |
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fema | 2010 |
Limitations of the HOMA-B score for assessment of beta-cell functionality in interventional trials-results from the PIOglim study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug | 2010 |
PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
Topics: Adiponectin; Aged; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; | 2011 |
Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients.
Topics: Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Femal | 2011 |
Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes.
Topics: Administration, Oral; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Homeostasis; Humans; | 2012 |
Efficacy and safety of glimepiride as initial treatment in Chinese patients with Type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Blood Glucose; Body Weight; China; Diabetes Mellitus, Type 2; Female; Glyca | 2013 |
Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Female; Glucose Clamp Technique; | 2002 |
Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects.
Topics: Adiponectin; Aged; Diabetes Mellitus, Type 2; Dinoprost; Female; Humans; Hypoglycemic Agents; Insuli | 2003 |
Effects of glimepiride on insulin secretion and sensitivity in patients with recently diagnosed type 2 diabetes mellitus.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin | 2004 |
Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; | 2004 |
Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; India; Insulin; Insulin Resis | 2004 |
Efficacy of glimepiride in Japanese type 2 diabetic subjects.
Topics: Aged; Asian People; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fe | 2005 |
Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control.
Topics: Biomarkers; Blood Glucose; Case-Control Studies; Humans; Hypoglycemic Agents; Insulin Resistance; In | 2005 |
Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
Topics: Analysis of Variance; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Dou | 2005 |
Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride.
Topics: Adiponectin; Aged; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Resp | 2006 |
Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis.
Topics: Adipocytes; Aged; Atherosclerosis; Cytokines; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; | 2006 |
Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Topics: Adiponectin; Analysis of Variance; Biomarkers; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, | 2007 |
Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes.
Topics: Adiponectin; Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycat | 2008 |
Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Res | 2008 |
17 other studies available for glimepiride and Insulin Resistance
| Article | Year |
|---|---|
Low-dose lixisenatide protects against early-onset nephropathy induced in diabetic rats.
Topics: Animals; Antioxidants; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Diet, Hi | 2020 |
Glimepiride treatment in a patient with type A insulin resistance syndrome due to a novel heterozygous missense mutation in the insulin receptor gene.
Topics: Adolescent; Amino Acid Sequence; Blood Glucose; Female; Heterozygote; Humans; Hypoglycemic Agents; I | 2018 |
Glimepiride Administered in Chow Reversibly Impairs Glucose Tolerance in Mice.
Topics: Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Female; Gluconeogenes | 2018 |
The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data.
Topics: Adamantane; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Female; Humans; H | 2019 |
Lost in translation: modulation of the metabolic-functional relation in the diabetic human heart.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty A | 2009 |
Triple verses glimepiride plus metformin therapy on cardiovascular risk biomarkers and diabetic cardiomyopathy in insulin resistance type 2 diabetes mellitus rats.
Topics: Animals; Biomarkers; Cardiomyopathies; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Ther | 2009 |
Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Human | 2010 |
[Evaluation of the efficiency and safety of therapy with a combination of sulfonylurea derivatives and insulin sensitizers for type 2 diabetes mellitus].
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Insulin Resistance; Male; Midd | 2012 |
[Warning signals insulin resistance. Insulin resistance causes not only diabetes].
Topics: Adolescent; Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Human | 2004 |
Insulin resistance determines efficacy of glimepiride in Type 2 diabetic patients not well controlled by diet alone.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; M | 2005 |
Glimepiride enhances intrinsic peroxisome proliferator-activated receptor-gamma activity in 3T3-L1 adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Animals; Cell Differentiation; Dose-Response Relationship, Dr | 2005 |
Low-dose metformin improves hyperglycaemia related to myotonic dystrophy.
Topics: Blood Glucose; C-Peptide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin | 2005 |
[Effects of glimepiride and metformin on free fatty acid in patients with Type 2 diabetes mellitus].
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Humans; Insulin Resistan | 2004 |
[Hardly any hypoglycemias, constant weight--and still cost effective].
Topics: Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drugs, Generic; Glyburide; Humans; Hy | 2005 |
[Clinical utilization of combined rosiglitazone and glimepiride in the treatment of type 2 diabetes mellitus].
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin | 2007 |
Glimepiride as insulin sensitizer: increased liver and muscle responses to insulin.
Topics: Animals; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin Resistance; Liver; Muscle, Skeleta | 2008 |
The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation, and dephosphorylation in insulin-resistant rat adipocytes in vitro.
Topics: Adipocytes; Animals; Biological Transport; Cell Membrane; Cells, Cultured; Epididymis; Glucose; Gluc | 1993 |